Log in

Relevant bibliographies by topics / Denosumab / Journal articles

To see the other types of publications on this topic, follow the link: Denosumab.

Journal articles on the topic 'Denosumab'

Author: Grafiati

Published: 4 June 2021

Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Denosumab.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

&NA;. "Denosumab." Reactions Weekly &NA;, no. 1358 (July 2011): 15. http://dx.doi.org/10.2165/00128415-201113580-00056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Tolman, Cae. "Denosumab." Australian Prescriber 34 (June 1, 2011): 63–66. http://dx.doi.org/10.18773/austprescr.2011.037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Denosumab." Reactions Weekly &NA;, no. 1415 (August 2012): 19. http://dx.doi.org/10.2165/00128415-201214150-00067.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

&NA;. "Denosumab." Reactions Weekly &NA;, no. 1416 (August 2012): 20. http://dx.doi.org/10.2165/00128415-201214160-00064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

TIKOO, DEEPIKA, and GUPTA MEENAKSHI. "DENOSUMAB:." Professional Medical Journal 19, no. 02 (February 22, 2012): 141–44. http://dx.doi.org/10.29309/tpmj/2012.19.02.2027.

Full text

Abstract:

Osteoporosis is the most common metabolic bone disease in developed countries. One of its major problems is the long termmorbidity and poor quality of life of patients. Receptor activator of nuclear factor-kB, its ligand and osteoprotegrin pathway plays an importantrole in bone remodeling. Receptor activator of nuclear factor-kB interacts with receptor activator of nuclear factor-kB ligand leading to activationof osteoclasts. Denosumab, a fully monoclonal antibody to receptor activator of nuclear factor-kB ligand prevents its binding to receptoractivator of nuclear factor-kB and can effectively suppress the bone loss in osteoporosis. Various clinical studies have shown that Denosumabhas good efficacy in decreasing bone resorption and has a favourable safety profile also.

APA, Harvard, Vancouver, ISO, and other styles

6

Moen, Marit D., and Susan J. Keam. "Denosumab." Drugs & Aging 28, no. 1 (January 2011): 63–82. http://dx.doi.org/10.2165/11203300-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Muir, Victoria J., and Lesley J. Scott. "Denosumab." BioDrugs 24, no. 6 (December 2010): 379–86. http://dx.doi.org/10.2165/11203310-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Scott, Lesley J., and Victoria J. Muir. "Denosumab." Drugs 71, no. 8 (May 2011): 1059–69. http://dx.doi.org/10.2165/11207370-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Dubois, Eline A., Robert Rissmann, and Adam F. Cohen. "Denosumab." British Journal of Clinical Pharmacology 71, no. 6 (May 12, 2011): 804–6. http://dx.doi.org/10.1111/j.1365-2125.2011.03969.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

&NA;. "Denosumab." Reactions Weekly &NA;, no. 1306 (June 2010): 19. http://dx.doi.org/10.2165/00128415-201013060-00062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Cada, Dennis J., Terri L. Levien, and Danial E. Baker. "Denosumab." Hospital Pharmacy 45, no. 10 (October 2010): 785–96. http://dx.doi.org/10.1310/hpj4510-785.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Rizzoli, René, Uma Yasothan, and Peter Kirkpatrick. "Denosumab." Nature Reviews Drug Discovery 9, no. 8 (August 2010): 591–92. http://dx.doi.org/10.1038/nrd3244.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Grimer, R. J. "Denosumab." Bone & Joint 360 2, no. 5 (October 2013): 43–44. http://dx.doi.org/10.1302/2048-0105.25.360183.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Lipton, Allan, and Ira Jacobs. "Denosumab." Current Opinion in Supportive and Palliative Care 5, no. 3 (September 2011): 258–64. http://dx.doi.org/10.1097/spc.0b013e328349731c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Pfeiffer, Naomi. "Denosumab." Oncology Times 3, no. 1 (January 2006): 18. http://dx.doi.org/10.1097/01434893-200601000-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Wilcock, Andrew, Sarah Charlesworth, Claire Stark Toller, Rahul Girish, Mary Mihalyo, and Paul Howard. "Denosumab." Journal of Pain and Symptom Management 56, no. 2 (August 2018): 295–301. http://dx.doi.org/10.1016/j.jpainsymman.2018.05.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Rogol, Elizaveta V., Scott Jun, Cory J. Broehm, and Jessica Belmonte. "Aggressive Central Giant Cell Granuloma of the Jaw and Adjuvant Denosumab Therapy: Decreased Morbidity and Preserved Function in a 3 Patient Case Series." FACE, September 7, 2022, 273250162211213. http://dx.doi.org/10.1177/27325016221121356.

Full text

Abstract:

We show the benefits of denosumab as adjuvant treatment of gnathic central giant cell granulomas (CGCGs) in 3 female patients, ages 18 to 65. This case series contributes to the growing experience in the medical therapy of these aggressive lesions, and demonstrates denosumab’s potential to decrease surgical morbidity. Central giant cell lesions of the jaw can be locally aggressive and thereby result in severe tissue destruction. Several medications have been evaluated as adjuvant therapy for CGCGs, with investigation of denosumab being the most recent. Our goal was to definitively treat patients with large CGCGs while minimizing unnecessary tissue and function loss. All 3 patients were offered adjuvant therapy with denosumab, since surgical resection alone would have resulted in large segmental defects requiring jaw reconstruction with free tissue transfer. Treatment instead consisted of lesion curettage and adjuvant denosumab therapy. The denosumab treatment protocol we used was based on what is currently recommended for unresectable giant cell tumors of bone (GCTB). Patients have been monitored for 40 months with clinical and radiographic exams, and 2 of them have also had histological evaluation following initiation of denosumab treatment. The 3 patients improved subjectively after the first few denosumab injections and had objective clinical and radiographic improvement after less than 6 months of therapy. Medication treatment length ranged from 10 to 15 months. Radiographic exams showed cortical thickening, resolution of cortical perforations, and calcification within a previously radiolucent region. Our findings are consistent with previous reports, and further support for the use of denosumab in locally aggressive central giant cell lesions. Our patients have thus far avoided large segmental resections, temporomandibular joint disarticulation, and sensory loss which would have resulted from surgical treatment alone. These 3 cases show that denosumab can be effective as adjuvant therapy in the treatment of aggressive gnathic CGCGs.

APA, Harvard, Vancouver, ISO, and other styles

18

"Denosumab." Reactions Weekly 1838, no. 1 (January 2021): 178. http://dx.doi.org/10.1007/s40278-021-89497-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

"Denosumab." Reactions Weekly 1838, no. 1 (January 2021): 180. http://dx.doi.org/10.1007/s40278-021-89499-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

"Denosumab." Reactions Weekly 1840, no. 1 (January 2021): 147. http://dx.doi.org/10.1007/s40278-021-90290-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

"Denosumab." Reactions Weekly 1837, no. 1 (January 2021): 206. http://dx.doi.org/10.1007/s40278-021-88805-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

"Denosumab." Reactions Weekly 1837, no. 1 (January 2021): 205. http://dx.doi.org/10.1007/s40278-021-88804-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

"Denosumab." Reactions Weekly 1850, no. 1 (April 2021): 114. http://dx.doi.org/10.1007/s40278-021-93919-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

"Denosumab." Reactions Weekly 1851, no. 1 (April 2021): 130. http://dx.doi.org/10.1007/s40278-021-94220-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

"Denosumab." Reactions Weekly 1851, no. 1 (April 2021): 131. http://dx.doi.org/10.1007/s40278-021-94221-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

"Denosumab." Reactions Weekly 1856, no. 1 (May 2021): 170. http://dx.doi.org/10.1007/s40278-021-96163-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

"Denosumab." Reactions Weekly 1857, no. 1 (May 2021): 130. http://dx.doi.org/10.1007/s40278-021-96515-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

"Denosumab." Reactions Weekly 1848, no. 1 (March 2021): 154. http://dx.doi.org/10.1007/s40278-021-93156-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

"Denosumab." Reactions Weekly 1846, no. 1 (March 2021): 101. http://dx.doi.org/10.1007/s40278-021-92349-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

"Denosumab." Reactions Weekly 1852, no. 1 (April 2021): 162. http://dx.doi.org/10.1007/s40278-021-94615-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

"Denosumab." Reactions Weekly 1852, no. 1 (April 2021): 163. http://dx.doi.org/10.1007/s40278-021-94616-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

"Denosumab." Reactions Weekly 1913, no. 1 (July 2022): 175. http://dx.doi.org/10.1007/s40278-022-18325-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

"Denosumab." Reactions Weekly 1913, no. 1 (July 2022): 176. http://dx.doi.org/10.1007/s40278-022-18326-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

"Denosumab." Reactions Weekly 1915, no. 1 (July 2022): 163. http://dx.doi.org/10.1007/s40278-022-19192-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

"Denosumab." Reactions Weekly 1919, no. 1 (August 13, 2022): 221. http://dx.doi.org/10.1007/s40278-022-21163-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

"Denosumab." Reactions Weekly 1919, no. 1 (August 13, 2022): 222. http://dx.doi.org/10.1007/s40278-022-21164-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

"Denosumab." Reactions Weekly 1916, no. 1 (July 2022): 173. http://dx.doi.org/10.1007/s40278-022-19632-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

"Denosumab." Reactions Weekly 1916, no. 1 (July 2022): 172. http://dx.doi.org/10.1007/s40278-022-19631-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

"Denosumab." Reactions Weekly 1916, no. 1 (July 2022): 174. http://dx.doi.org/10.1007/s40278-022-19633-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

"Denosumab." Reactions Weekly 1917, no. 1 (July 2022): 217. http://dx.doi.org/10.1007/s40278-022-20088-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

"Denosumab." Reactions Weekly 1921, no. 1 (August 27, 2022): 112. http://dx.doi.org/10.1007/s40278-022-22106-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

"Denosumab." Reactions Weekly 1925, no. 1 (September 24, 2022): 206. http://dx.doi.org/10.1007/s40278-022-23983-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

"Denosumab." Reactions Weekly 1907, no. 1 (May 2022): 169. http://dx.doi.org/10.1007/s40278-022-15428-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

"Denosumab." Reactions Weekly 1927, no. 1 (October 8, 2022): 214. http://dx.doi.org/10.1007/s40278-022-24950-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

"Denosumab." Reactions Weekly 1924, no. 1 (September 17, 2022): 181. http://dx.doi.org/10.1007/s40278-022-23534-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

"Denosumab." Reactions Weekly 1924, no. 1 (September 17, 2022): 184. http://dx.doi.org/10.1007/s40278-022-23537-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

"Denosumab." Reactions Weekly 1924, no. 1 (September 17, 2022): 182. http://dx.doi.org/10.1007/s40278-022-23535-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

"Denosumab." Reactions Weekly 1924, no. 1 (September 17, 2022): 183. http://dx.doi.org/10.1007/s40278-022-23536-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Denosumab." Reactions Weekly 1923, no. 1 (September 10, 2022): 178. http://dx.doi.org/10.1007/s40278-022-23041-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"Denosumab." Reactions Weekly 1923, no. 1 (September 10, 2022): 179. http://dx.doi.org/10.1007/s40278-022-23042-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!